 Etravirine is a second generation non-nucleoside analogue reverse transcriptase inhibitor NNRTI approved by the U.S. Food and Drug Administration FDA in January 2008 and by the European Medicines Agency in September 2008 for clinical use in adults with incomplete virologic suppression and resistance to previous NNRTI and other antiretroviral classes. 